Date: 2014-05-22
Type of information: Credit line
Company: Mucosis (The Netherlands)
Investors: the Netherlands Enterprise Agency (The Netherlands)
Amount: up to €5 million
Funding type: credit line
Planned used: Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM® prefusion F RSV vaccine candidate through human proof-of-concept studies. These studies aim to demonstrate both safety and protection against a challenge with RSV in healthy volunteers.
Others: * On May 22, 2014, Mucosis announced that it has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.
Therapeutic area: Infectious diseases
